source
- Jazz turns to AbCellera for T cell engagers in up to $4.1B partnershipFor much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen clinical-stage drug candidate…Endpoints · 2mo ago↗ source
- Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophyA startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that is broken or missing in people born with…Endpoints · 2mo ago↗ source
- Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsTriveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and incl…